Cerebrovascular complications in pediatric intensive care unit

Anil Sachdev, Rachna Sharma, Dhiren Gupta

Abstract

Cerebrovascular complications are being frequently recognized in the pediatric intensive care unit in the recent few years. The epidemiology and risk factors for pediatric stroke are different from that of the adults. The incidence of ischemic stroke is almost slightly more than that of hemorrhagic stroke. The list of diagnostic causes is increasing with the availability of newer imaging modalities and laboratory tests. The diagnostic work up depends on the age of the child and the rapidity of presentation. Magnetic resonance imaging, computerized tomography and arteriography and venography are the mainstay of diagnosis and to differentiate between ischemic and hemorrhagic events. Very sophisticated molecular diagnostic tests are required in a very few patients. There are very few pediatric studies on the management of stroke. General supportive management is as important as the specific treatment. Most of the treatment guidelines and suggestions are extrapolated from the adult studies. Few guidelines are available for the use of anticoagulants and thrombolytic agents in pediatric patients. So, our objective was to review the available literature on the childhood stroke and to provide an insight into the subject for the pediatricians and critical care providers.

Keywords: Anticoagulant therapy, cerebrovascular accident, childhood stroke, pediatric intensive care unit, stroke, thrombolytic therapy

Introduction

Cerebrovascular accident in children is more common than was once recognized. It is typically associated with an underlying anatomic anomaly or a systemic disease. The cerebrovascular complications are due to any abnormality of the brain resulting from a pathologic process of the blood vessels, e.g., occlusion of the lumen by a thrombus or embolus, rupture of the vessel, any lesion or altered permeability of the vessel wall and increased viscosity or other change in quality of blood.

This review article is presented since there are few pediatric studies on childhood stroke and clear guidelines are not available to deal with such patients in the pediatric intensive care. A search of publications listed in the electronic databases PubMed and OVID was conducted using the keywords like stroke, childhood stroke, cerebrovascular accident, thrombolytic therapy and anticoagulant therapy. We preferred to select studies on pediatric stroke particularly and also studies on adults with reference to children. The relevant cross-references from the eligible articles were also searched manually. Some articles were also obtained manually from National Medical Library, New Delhi. The selection of studies was based on study title initially, followed by the abstract and full body text. Two hundred studies were selected on the basis of study title. This was reduced to 130 after abstract search and 65 full text articles were selected and read.

Epidemiology

It is a general impression that childhood cerebrovascular diseases are more often underdiagnosed as compared to that of the adult population. The overall average
annual incidence rate for children through 14 years of age was 2.52/100,000/year. Broderick et al, found an incidence of 2.7 cases/100,000/year, similar to the figure reported previously by Schoenberg and colleagues. In the Canadian Pediatric Ischemic Stroke Registry, incidence of arterial and venous occlusion is estimated to be 1.2/100,000 children/year.

**Risk Factors**

Strokes in children occur in conjunction with intracranial infection, arteriovenous malformations (AVMs) or with occlusive vascular diseases secondary to cardiac disease, hematological and metabolic disorders. Central nervous system infections and trauma remain the major causes of stroke in children. Despite extensive evaluation, an etiologic factor or associated conditions remain undetermined in 20–50% of all stroke patients [Table 1]. The incidence of stroke in pediatric cardiac patients is 4% with 75% occurring within the first two years of life.

Vascular malformations, including AVMs, aneurysms, and cavernous malformations are the most common surgically treatable risk factors for children with hemorrhagic stroke [Figure 1]. Hematological disorders leading to hyperviscosity syndromes (polycythemia, hyperleukocytosis, and thrombocytosis) can lead to arterial occlusion.

**Table 1: Risk factors for pediatric cerebrovascular disease**

| Cardiac causes                        | Hematologic disorders and coagulopathies |
|---------------------------------------|------------------------------------------|
| Congenital heart disease              | Hemoglobinopathies (sickle cell anemia)  |
| Ventricular septal defect             | Immune thrombocytopenic purpura           |
| Atrial septal defect                  | Thrombotic thrombocytopenic purpura       |
| Patent ductus arteriosus             | Thrombocytosis                            |
| Aortic stenosis                       | Polycythemia                              |
| Mitral stenosis                       | Disseminated intravascular coagulation    |
| Coarctation                           | Leukemia or other neoplasm                |
| Cardiac rhabdomyoma                   | Congenital coagulation defects            |
| Complex congenital heart defects      | Oral contraceptive use                    |
| Acquired heart disease                | Pregnancy and the postpartum period       |
| Rheumatic heart disease               | Antithrombin III deficiency                |
| Prosthetic heart valve                | Protein S deficiency                      |
| Libman–Sacks endocarditis            | Protein C deficiency                      |
| Bacterial endocarditis                | Congenital serum C2 deficiency            |
| Cardiomyopathy                        | Liver dysfunction with coagulation defect  |
| Myocarditis                           | Vitamin K deficiency                      |
| Atrial myxoma                         | Lupus anticoagulant                       |
| Arrhythmia                            | Anticardiolipin antibodies                 |
| Systemic vascular diseases            | Structural anomalies                      |
| Systemic hypertension                 | Arterial fibromuscular dysplasia          |
| Volume depletion or systemic hypotension| Agenesis or hypoplasia of the internal carotid or vertebral arteries |
| Hypernatremia                         | Arteriovenous malformation                |
| Superior vena cava syndrome           | Hereditary hemorrhagic telangiectasia      |
| Diabetes                              | Sturge–Weber syndrome                     |
| Vasculitis                            | Intracranial aneurysm                     |
| Meningitis (bacteria, tuberculosis, fungi) | Trauma                                 |
| Systemic infection                    | Fat or air embolism                       |
| Systemic lupus erythematosus          | Foreign body embolism                     |
| Polyarteritis nodosa                  | Carotid ligation (e.g., ECMO)             |
| Granulomatous angiitis                | Vertebral occlusion following abrupt cervical rotation |
| Takayasu’s arteritis                  | Child abuse                               |
| Rheumatoid arthritis                  | Post-traumatic arterial dissection        |
| Dermatomyositis                       | Blunt cervical arterial trauma            |
| Inflammatory bowel disease            | Arteriography                             |
| Drug abuse (cocaine, amphetamines)    | Post-traumatic carotid cavernous fistula  |
| Hemolytic-uremic syndrome             | Coagulation defect with minor trauma      |
| Vasculopathies                        | Amniotic fluid/placental embolism         |
| Ehlers–Danlos syndrome                | Penetrating intracranial trauma           |
| Homocystinuria                        |                                         |
| Moyamoya syndrome                     |                                         |
| Fabry’s disease                       |                                         |
| Malignant atrophic papulosi           |                                         |
| Pseudoxanthoma elasticum              |                                         |
| NADH-CoQ reductase deficiency         |                                         |
| Vasospastic disorders                 |                                         |
| Migraine, ergot poisoning, vasospasm with subarachnoid hemorrhage | |
There has been a recent recognition of the importance of hypercoagulable states. Antithrombin III, proteins C and S are naturally occurring anticoagulants whose deficiencies are inherited as an autosomal recessive trait. Autoimmune disorders may lead to cerebrovascular disease through a vasculitis or by inducing a hypercoagulable state. In systemic lupus erythematosus, neurologic involvement is seen in over 50% of patients.

Several inborn errors of metabolism are associated with cerebral infarction. Homocystinuria, due to a defect in methionine metabolism, may present as a thrombotic syndrome due to endothelial damage and increased platelet aggregation. Stroke-like episodes in a nonvascular distribution are seen in mitochondrial encephalomyopathy with lactic acidemia (MELAS). This recently described disorder is due to a mutation of mitochondrial DNA and a tentative diagnosis can be made by the presence of ragged red fibers in skeletal muscle.

Trauma to the neck may predispose to carotid thrombosis. This can be a blunt injury to the neck, intraoral trauma, falling with a pencil in the mouth, or trauma to the cervical spine (chiropractic manipulation).

Moyamoya disease occurs primarily in the Japanese population, and is characterized by progressive stenosis and occlusion of the cerebral arteries at the Circle of Willis. In response to the stenosis, an abnormal network of small collateral vessels develops, creating the characteristic "puff of smoke" appearance on angiograms. Children with Moyamoya disease present with recurrent transient ischemic attacks as well as acute ischemic stroke. In general, there is a progressive neurologic deterioration that is characterized by significant impairment of motor and cognitive function. The majority of cases are idiopathic. Moyamoya syndrome is a disorder with a similar angiographic appearance to Moyamoya disease but is secondary to several slowly progressive occlusive cerebral vasculopathies, such as sickle cell disease, postradiation vasculopathy and neurofibromatosis.

Newborn illnesses that increase the risk of sino-venous thrombosis include asphyxia, dehydration, sepsis, and head and neck disorders, including meningitis. In children, acute illnesses like sepsis or dehydration are present in one-third of the cases of sinus thrombosis. Head trauma or cranial surgery may damage dural sinuses, triggering thrombosis. Chronic systemic inflammatory diseases are the underlying risk factor in 60% of the patients with cerebro-sinovenous thrombosis (CSVT).

**Pathophysiology**

Strokes are broadly classified as either hemorrhagic or ischemic, but may also be caused by decrease in cerebral blood flow. Acute ischemic stroke refers to strokes caused by thrombosis or embolism and accounts for 85% of all strokes. Thrombotic strokes can be divided into large vessel disease, including the carotid artery system, or small vessel disease comprising the intracerebral arteries, including the branches of the Circle of Willis and the posterior circulation. The most common sites of thrombotic occlusion are cerebral artery branch points, especially in the distribution of the...
internal carotid artery.\textsuperscript{[23]} Cerebral hemorrhage [Figure 2] may occur when an artery in the brain tears or bursts, causing blood to spill out. A hemorrhage often happens without warning. In children, it may result from blood vessel defects like aneurysm or an AVM present since birth. Very rarely, it may occur as a result of high blood pressure.\textsuperscript{[24]}

Loss of perfusion to a portion of the brain initiates the ischemic cascade within seconds to minutes. Within the ischemic cerebrovascular bed, there are two major zones of injury: the core ischemic zone of necrosis and the potentially reversible “ischemic penumbra”. Due to inadequate supply and rapid depletion of oxygen and glucose in the core zone, the neurons and the supporting tissues (glial cells) undergo necrosis. The cells in the penumbra zone suffer mild to moderate ischemia due to the presence of collateral circulation. Restoration of perfusion to ischemic penumbra is the earliest goal of treatment of ischemic stroke.\textsuperscript{[25]}

Cellular changes during the ischemic event involve a series of complex metabolic changes. The duration, severity, and the location of focal cerebral ischemia determine the extent of brain function and thus the severity of stroke. Once the blood flow to the neurons diminishes, anaerobic glycolytic pathways are utilized in the affected region and hydrogen ions and lactic acid are produced leading to generation of free radicals, arachidonic acid, nitric oxide and cytokines [Figure 3].\textsuperscript{[26,27]}

**Clinical Manifestation**

The signs and symptoms depend on the location and size of the occluded vessel, as well as the patient’s age. Anterior circulation strokes are much more common than posterior, and the left cerebral hemisphere is affected more often than the right.\textsuperscript{[28]}

Most children who have suffered a stroke present with hemiparesis with or without seizures. Seizures at the onset of stroke are relatively frequent in children as compared to adults.\textsuperscript{[29]} A prolonged persistent focal deficit following seizures that is inconsistent with Todd paresis raises the possibility of stroke. Gaze palsy or head turning suggests a large supratentorial infarct. If headache is present, arterial dissection or venous thrombosis is the possible cause. Deterioration in the level of consciousness is common in cerebral hemorrhage, large middle cerebral territory infarcts, and posterior fossa strokes, and is an indication for immediate transfer to an intensive care unit with pediatric neurology and neurosurgery facilities available.\textsuperscript{[30]}

The clinical findings of ischemic and hemorrhagic stroke overlap, so a brain imaging study is mandatory to distinguish ischemic stroke from hemorrhage or other structural brain lesions that may imitate stroke. Hemiplegia, headache, seizure or altered levels of consciousness may all herald a potentially reversible or lethal medical or surgical stroke emergency. The time from onset of symptoms to presentation is very useful diagnostically,
for example, arteriopathy is more likely to present with a stuttering onset, and “thunderclap” headaches may be indicative of a subarachnoid hemorrhage.

The chance of hemorrhagic stroke is more if a child presents with headache, nausea, vomiting, coma, hemiparesis, seizures and skin lesions. The clinical presentation of acute ischemic stroke more commonly has associated cranial nerve palsy (VII, IX, X, XII, Horner), visual field defects along with hemiparesis, seizures, headache, ataxia and coma.[24]

Middle cerebral artery occlusions commonly produce contralateral hemiparesis, contralateral hypesthesia, ipsilateral hemianopsia and gaze preference towards the side of the lesion. Agnosia is common, and receptive or expressive aphasia may result if the lesion occurs in the dominant hemisphere. Since the middle cerebral artery supplies the upper extremity motor strip, weakness of the arm and face is usually worse than that of the lower limb.[31]

Anterior cerebral artery occlusions primarily affect frontal lobe function and can result in disinhibition and speech perseveration, producing primitive reflexes (e.g., grasping, sucking reflexes), altered mental status, impaired judgment, contralateral weakness (greater in legs than in arms), contralateral cortical sensory deficits, gait apraxia, and urinary incontinence.[32]

Posterior cerebral artery occlusions affect vision and thought process, producing contralateral homonymous hemianopsia, cortical blindness, visual agnosia, altered mental status, and impaired memory.[33]

Vertebrobasilar artery occlusions are notoriously difficult to detect because they cause a wide variety of cranial nerve, cerebellar, and brainstem deficits.[34] These include vertigo, nystagmus, diplopia, visual field deficits, dysphagia, dysarthria, facial hypesthesia, syncope, and ataxia. A hallmark of posterior circulation strokes is that there are crossed findings: ipsilateral cranial nerve deficits and contralateral motor deficits. This is in contrast to anterior strokes, which produce findings on one side of the body only.

Lastly, lacunar strokes result from occlusion of the small, perforating arteries of the deep subcortical areas of the brain, accounting for 13–20% of all cerebral infarctions. The most common lacunar syndromes include pure motor, pure sensory and ataxic hemiparetic strokes. These infarcts commonly occur in patients with small vessel disease, such as diabetes and hypertension, and do not lead to impairments in cognition, memory, speech, or level of consciousness.[35]

The clinical features of cerebro-sinovenous thrombosis are subtle and present with diffuse neurologic signs and symptoms such as headache, altered sensorium and papilledema in 90% of patients, while seizures are present in 48% and hemiparesis in 17% only.[36,37]

**Laboratory Investigations**

The sequence of investigations depends on the clinical presentation and the duration of onset of stroke [Table 2]. Magnetic resonance imaging (MRI) is an ideal method to evaluate neonates, infants, and children with suspected cerebral ischemia. MR angiography can confirm vessel patency and define the vascular anatomy. However,

| Table 2: Laboratory investigations in pediatric stroke |
|-----------------------------------------------|
| **First line tests (within 24 hours)** | **Second line tests (within first week if indicated)** | **Third line tests (Electively)** |
| Magnetic resonance imaging | ECG, ECHO, Carotid Doppler, Holter | HIV, mycoplasma, |
| Magnetic resonance angiography | Hypercoagulable state | Lyme disease, Cat scratch |
| Computerized tomography with | Protein C and S (activity, antigen) | Serology |
| Angiography | Antithrombin III | Cardiac MRI |
| Conventional angiography | Anticardiolipin antibodies | Transesophageal ECHO |
| Other tests | Antiphospholipid antibodies | Cerebral angiogram |
| Complete blood counts, ESR | Factor V (leiden) mutation | Muscle biopsy |
| PT/PTT, | Lupus anticoagulant | Leptomeningeal biopsy |
| Blood sugar | Rheumatoid factor | DNA study for MELAS |
| LFT, KFT | Serum aminocids | Serum homocysteine |
| Serum electrolytes | Complement profile | |
| Chest X-ray | Hb electrophoresis | |
| ANA | Urine for organic acids | |
| Urinalysis | Serum lactate, pyruvate, ammonia | |
| Urine drug screen | CSF analysis | |
| | Lipid profile | |

PT, prothrombin time; APPT, activated partial thromboplastin time; ANA, antinuclear antibody; MELAS, mitochondrial encephalomyopathy with lactic acidemia
the rapid acquisition time and ease of monitoring make computerized tomography (CT) the ideal imaging technique in an unstable patient or a patient in whom acute intracranial hemorrhage is likely.\[38\]

**Management**

Acute treatment of cerebral ischemia requires an intensive care unit setting. Treatment should be directed to the underlying cause if it is identifiable. CT or MRI scan of the brain is essential to determine whether stroke is ischemic or hemorrhagic. The management is essentially aggressive supportive care to prevent neurological sequelae.\[39\] (Table 3)

**Oxygenation**

Maintenance of airway, breathing, and circulation are the first priority in any acutely ill child. Studies on oxygenation in childhood arterial ischemic stroke are lacking, but a single consensus guideline from the Royal College of Physicians (RCP) advises that oxygen saturation should be maintained within normal limits. Supplement oxygen by mask or hood should be provided when oxygen saturation is <92%, and endotracheal intubation and mechanical ventilation should be instituted in patients with severe hypoxia and hemodynamic instability.\[40,41\]

**Blood pressure**

Elevated blood pressure should not be treated very promptly within the first days after ischemic stroke. The ischemic penumbra loses autoregulation, and perfusion is directly linked to the mean arterial pressure. Acute elevations in blood pressure are often transient, and spontaneous declines are common. Overzealous treatment of hypertension following arterial ischemic stroke can convert the ischemic penumbra into an infarct. Reduction of blood pressure greater than 20 mmHg has been associated with worse neurological outcomes and larger infarcts, leading to the suggestion that even extreme cases of hypertension should be reduced by only 15% in the first 24 hours.\[42\]

If antihypertensive therapy is necessary, agents that have a rapid onset and predictable response should be used. If a child presents with hypotension, prompt treatment with fluid boluses and ionotropic vasopressors should be instituted to maintain mean blood pressure.\[43\]

**Temperature**

In patients with acute stroke, fever is not uncommon. Fever should be taken care of with prompt use of antipyretics. Even mild elevations in body temperature consistently worsen the neurologic outcome from
ischemic insults.\cite{14,45} Induced hypothermia is a potential treatment strategy for adult arterial ischemic stroke and it improves outcomes of neonates with hypoxic ischemic encephalopathy.\cite{46}

**Euglycemia**

There is strong evidence that hyperglycemia and hypoglycemia are associated with poor outcomes in adult arterial ischemic stroke studies.\cite{47} A similar recommendation has been made for pediatric stroke.\cite{48}

Hyperglycemia induces a pro-oxidative and proinflammatory state that can cause direct neuronal toxicity and cerebral edema. It is also responsible for procoagulant state and may further affect penumbral area blood supply. Besides lowering blood sugar, insulin has antioxidant and anti-inflammatory effects. Insulin also improves nitric oxide production and results in improved blood circulation to the ischemic areas.

**Increased intracranial pressure**

Acute management of large-distribution arterial ischemic stroke in children and adults often involves management of increased intracranial pressure secondary to edema and/or mass effect on the ventricles during the first 72–96 hours after a large infarct. The American Heart Association (AHA) suggests decompressive surgery for the seriously affected patients after adequate counseling of the family,\cite{40} while the RCP recommends early neurosurgical referral in children with deteriorating sensorium. Unfortunately, evidence and guidelines in childhood stroke are lacking.\cite{49}

**Blood transfusion**

For children with sickle cell disease, who have ischemic stroke, exchange transfusion is required to reduce hemoglobin S levels to <30% total hemoglobin, and thereafter, regular transfusion (4–6 weekly) to keep hemoglobin S to <20% is required.\cite{50}

**Recommendations for Supportive Therapy After Stroke in Children**

The recommendations are discussed below.\cite{38}

**Class I recommendation**

- The supportive measures include maintenance of normothermia, normoxemia, normoglycemia and control of systemic hypertension (Class I, Level of Evidence C).

**Class II recommendation**

- In children with stroke, it is reasonable to maintain euhydration and treat anemia (Class IIa, Level of Evidence C).

**Class III recommendations**

1. There is no role of supplemental oxygen in the absence of hypoxemia (Class III, Level of Evidence C).
2. There is no evidence suggesting the benefit of prophylactic antiepileptics in the absence of clinical or electrographic seizures in children with ischemic stroke (Class III, Level of Evidence C).
3. Hypothermia should not be used in children with stroke except in the context of a clinical trial as there

### Table 4: Antithrombotic management of adult and childhood arterial ischemic stroke

| Condition                                      | RCP pediatric guidelines\cite{62} | ACCP pediatric guidelines\cite{63} | AHA adult guidelines\cite{40} |
|------------------------------------------------|----------------------------------|----------------------------------|-------------------------------|
| Acute systemic thrombolysis                    | No specific guideline, but the following comment: “There is currently no evidence to support use of thrombolytic agents such as tissue plasminogen activator (tPA) in the acute treatment of arterial ischemic stroke in children.” | No specific guideline, but the following comment: “The use of thrombolytic agents in children with arterial ischemic stroke, however, has been rare, and the risk/benefit ratio is unknown at this time.” | Intravenous recombinant tPA (0.9 mg/kg: maximum dose 90 mg) is recommended for selected patients who may be treated within 3 hours of onset of ischemic stroke (Class I, Level of Evidence A) |
| Acute intra-arterial thrombolysis               | None                             | None                             | Intra-arterial thrombolysis is an option for treatment of selected patients who have major stroke of <6 hours duration because of occlusions of the MCA and who are not otherwise candidates for intravenous recombinant tPA (Class I, Level of Evidence B) |
| Acute, nonthrombolytic management of idiopathic arterial ischemic stroke | Aspirin (5 mg/kg/day) should be given once there is radiological confirmation of arterial ischemic stroke, except in patients with evidence of intracranial hemorrhage on imaging and those with sickle cell disease (strong consensus) | For children with arterial ischemic stroke, we suggest treatment with UFH or LMWH for 5–7 days and until cardioembolic stroke or vascular dissection has been excluded (grade 2C) | The oral administration of aspirin (initial dose 325 mg) within 24–48 hours after stroke onset is recommended for treatment of most patients (Class I, Level of Evidence A) |

RCP = Royal College of Physicians; ACCP = American College of Chest Physicians; AHA = American Heart Association; MCA = Middle cerebral artery; UFH = Unfractionated heparin; LMWH = Low-molecular-weight heparin
are no additional data confirming its safety and efficacy (Class III, Level of Evidence C).

**Thrombolytic therapy**

Tissue plasminogen activator (tPA) is used acutely in adult arterial ischemic stroke as a profibrinolytic agent, for lysing intracerebral clots and thereby restoring blood flow to compromised regions of the brain (Table 4). These patients are now routinely given systemic tPA when presenting within 3 hours of stroke onset. A dose of 0.9 mg/kg (maximum 90 mg) is used, with 10% of the dose given as a bolus over the first minute, and the remaining dose given as a 1-hour infusion.

There is currently no evidence to support the use of thrombolytic agents such as tPA in the acute treatment of pediatric arterial ischemic stroke. A prospective study by Browne et al., using 0.5 mg/kg/hour systemic recombinant tPA for 6 hours concurrently with heparin (10 U/kg/hour) and fresh frozen plasma supplementation prior to recombinant tPA infusion, reported complete resolution of thrombosis in 13 of 20 children (65%), partial resolution in 4 patients (20%), and no response in 3 patients (15%). Zenz et al., reported a dose of 0.5 mg/kg/hour for the first hour followed by 0.25 mg/kg/hour until clot lysis occurred or treatment had to be stopped because of bleeding complications. Complete clot lysis was achieved in 16 of 17 pediatric patients within 4–11 hours after the start of treatment. At this time, there is no evidence to suggest that there is an advantage of local over systemic thrombolytic therapy in children with thrombotic complications.

**Recommendations for Thrombolytic Therapy for Childhood Stroke**

The recommendations are discussed below.

**Class II recommendation**

In children with CVST, thrombolytic therapy with tPA can be considered (Class IIb, Level of Evidence C).

**Class III recommendation**

Thrombolytic therapy is not recommended for children with acute ischemic stroke outside a clinical trial (Class III, Level of Evidence C). However, there was no consensus about the use of tPA in older adolescents who otherwise meet standard adult tPA eligibility criteria.

**Antiplatelet aggregation**

The Joint Guideline Statement from the AHA and the American Academy of Neurology (AAN) recommends that aspirin should be given within 24–48 hours of stroke onset in most patients (Level of Evidence grade A).[40] The administration of aspirin as an adjunctive therapy, within 24 hours of the use of thrombolytic agents, is not recommended (grade A). Aspirin should not be used as a substitute for other acute interventions, especially t-PA (grade A). A low dose of 1–5 mg/kg/day for platelet aggregation inhibition has been proposed. Pediatric doses of aspirin are not based on studies of the effect on platelet function in pediatric patients.

Ticlopidine and clopidogrel selectively inhibit ADP-induced platelet aggregation, via the inhibition of the P2Y12 receptor. The antiplatelet effect of ticlopidine and clopidogrel is additive to that of aspirin. There has been no reported use in children, and dosage recommendations are unknown.

**Recommendations for Aspirin Use in Children with Stroke**

The recommendations are discussed below.

**Class II recommendations**

1. To prevent recurrence of acute ischemic stroke in children, aspirin can be used, except in cases where the underlying cause of stroke is sickle cell disease, severe hypercoagulable disorder and all those children who are at increased risk for embolization (Class IIa, Level of Evidence C).
2. A dose of 3–5 mg/kg/day is adequate for stroke prevention in children (Class IIa, Level of Evidence C). If dose-related side effects occur, then, a dose reduction to 1–3 mg/kg may be considered (Class IIb, Level of Evidence C).
3. In children taking aspirin for stroke prevention, it is reasonable to vaccinate for varicella and annually with influenza vaccine to reduce the risk of Reye’s syndrome (Class IIa, Level of Evidence C). During the period of varicella and influenza infection, it is reasonable to withhold aspirin (Class IIa, Level of Evidence C).

**Anticoagulants**

Heparins, including unfractionated heparin (UFH)
and low–molecular-weight heparin (LMWH), are the principal agents used in the acute phase of anticoagulant therapy for arterial ischemic stroke. Based on the high rates of prothrombotic abnormalities, cardioembolic stroke and vascular dissection in childhood arterial ischemic stroke, American College of Chest Physicians’ (ACCP) guidelines recommend treatment with UFH or LMWH for 5–7 days. However, this recommendation remains controversial, and the RCP recommends initial treatment of childhood arterial ischemic stroke with aspirin 5 mg/kg until an indication for anticoagulation is found. Parenteral anticoagulants should not be prescribed until a brain imaging study has excluded the possibility of a primary intracranial hemorrhage. UFH doses are age dependent, with younger children requiring greater average doses (20 U/kg/hour) than older children and adults; similar observations have been made for LMWHs. Bolus dosing of UFH is typically avoided in arterial ischemic stroke. In children, heparin therapy is monitored most accurately by antifactor Xa activity. For UFH, the therapeutic range is 0.35–0.7 antifactor Xa activity U/ml, whereas for LMWH, the therapeutic range is 0.5–1.0 U/ml. Side effects of UFH include bleeding, osteoporosis, and heparin induced thrombocytopenia. Burak et al. administered enoxaparin to eight children with stroke and concluded that the LMWH was a safe and effective alternative to heparin for children. Anticoagulants also are being explored as an adjunct to thrombolytic therapy.

Recommendations for LMWH in Children with Stroke

The recommendations are discussed below.

Class I recommendations

For long-term anticoagulation, LMWH can be used in all children with substantial risk of recurrent cardiac embolism, CVST, and selected hypercoagulable states (Class I, Level of Evidence C).

Class II recommendations

The administration of LMWH or UFH may be considered in children for up to 1 week after an ischemic stroke, pending further evaluation to determine the cause of the stroke (Class IIb, Level of Evidence C).

Recommendations for the Use of Warfarin in Children with Stroke

The recommendations are discussed below.

Class II recommendations

For long-term anticoagulation, warfarin can be used in all children with substantial risk of recurrent cardiac embolism, cervico-cephalic arterial dissection, CVST, and selected hypercoagulable states (Class IIa, Level of Evidence C).

Surgical intervention

Surgical decompression has been reported in children presenting in coma with large ischemic middle cerebral infarcts, which are almost always fatal if managed conservatively. Similar intervention is required for a large cerebellar infarction leading to brain stem compression and hydrocephalus.

Prevention of Stroke

The mechanisms and risk factors for arterial ischemic stroke in children are not well understood at present. The primary prevention is well established in few well-defined causes of arterial ischemic stroke, such as sickle cell disease, congenital cardiac lesions and hypercoagulable disorders.

1. In sickle cell disease, all the children between 2 and 16 years should have Transcranial Doppler study once in a year (Class IIa, Level of Evidence B). Borderline and mildly abnormal studies may be repeated in 3–6 months. Children with abnormal results should receive periodic transfusions to reduce the percentage of sickle hemoglobin (Class I, Level of Evidence A).

2. All children with congenital heart lesions, especially complex heart lesions, should be repaired both to improve cardiac function and to reduce the subsequent risk of stroke (Class I, Level of Evidence C).

3. Children with hypercoagulable disorders are at a risk of stroke only in the setting of an additional risk factor. However, it is reasonable to evaluate for elevated serum homocysteine levels and the more common prothrombotic states, and to start folate, vitamin B6, or vitamin B12 if homocysteine is found to be elevated.

Rehabilitation Techniques

Early evaluation of physical and cognitive disability is the key to prevent avoidable complications and to plan rehabilitation, which should involve a multidisciplinary team. Constraint therapy may be adapted for children and appears to be associated with improved function of a hemiparetic hand. Improvement occurs over a prolonged period of time, and late deterioration is rare. The child and family should be encouraged to express their main concerns about re-integration to the
home, community and school environments and to have these concerns addressed.\textsuperscript{63,66}

**Outcome, Morbidity and Mortality**

Between 20 and 40\% of children die after a stroke.\textsuperscript{67-72} The mortality is higher for the hemorrhagic (about a third) than for ischemic stroke (up to 20\%, with about half related to the underlying systemic illness rather than the stroke itself). Death during the acute phase is predicted by the level of consciousness on admission. Recurrent stroke occurs in 6–15\% of children and mortality is higher in this group.\textsuperscript{71,73,74} Intractable intracranial hypertension is a major predictor of poor outcome in patients with large intracerebral or intracerebellar hemorrhage and massive hemispheric or cerebellar infarction. Between 50 and 80\% of surviving children have neurological sequelae, most commonly hemiparesis.\textsuperscript{70,71,73-79} Neurological outcome appears to be better for those with hemorrhage, CVST, and posterior circulation stroke.\textsuperscript{72,78,81} Other problems include neuropsychological deficits, poor attention, behavioral problems, and poor quality of life.\textsuperscript{82-86} Predictors of poor neurological, cognitive, and behavioral outcome include systemic disease, multiple risk factors, infarct size, cortical involvement, thromboembolism, and Moyamoya.\textsuperscript{87,89}

**Our Experience at Sir Ganga Ram Hospital**

In the year 2009, from January to December, there were 794 admissions in the 12-bedded PICU. Of these, 135 cases had primary non-traumatic central nervous system ailment and only 15 cases presented with stroke. There were nine patients with arterial ischemic stroke and six had hemorrhagic stroke. Central nervous system infection was the predominant risk factor for ischemic stroke in six patients, two had severe dehydration and electrolyte imbalance, and one each with cyanotic heart disease and l-asparaginase induced stroke. There were three cases of hemorrhagic stroke due to malignancy and one each of AVM, middle cerebral artery aneurysm and late hemorrhagic disease of the newborn. Neuroimaging was done in all cases for the diagnosis and to differentiate ischemic from hemorrhagic stroke. All patients received supportive therapy, LMWH and aspirin for ischemic stroke while interventional neurosurgical procedures were done in three cases of hemorrhagic stroke. Thrombolytic therapy was not used in any case.

**Conclusions**

Intensive supportive management and rehabilitation techniques are critical components in the management of children with stroke to optimize outcomes. The pathophysiology and outcomes of adult stroke differ significantly from those in children. The therapeutic management currently remains similar, largely because of the paucity of evidence from devoted pediatric observational studies and clinical trials. The use of anticoagulants and thrombolytic agents has been insufficiently investigated in childhood stroke, resulting in a lack of guidance. Dedicated pediatric studies are critically necessary to establish a key evidence for the multifaceted management in childhood stroke.

**References**

1. Schoenberg BS, Mollinger LF, Schoenberg DG. Cerebrovascular disease in infants and children: A study of incidence, clinical features, and survival. Neurology 1978;28:763-8.
2. Broderick J, Talbot T, Prenger E, Leach A, Brett T. Stroke in children within a major metropolitan area. The surprising importance of intracranial hemorrhage. J Child Neurol 1995;8:259-65.
3. Deveber GA, Adams M, Andrew M. Canadian pediatric ischemic stroke registry. Can J Neurol Sci 1995;22:824.
4. Nicolaides P, Appleton RE. Stroke in children. Dev Med Child Neurol 1996;38:172-180.
5. Maneini J, Girard N, Chabrol B. Ischemic cerebrovascular disease in children: Retrospective study of 35 patients. J Child Neurol 1997;12:193-9.
6. Kerr LM, Anderson DM, Thompson JA, Lyver SM, Cull GK. Ischemic stroke in the young: Evaluation and age comparison of patients six months to thirty-nine years. J Child Neurol 1993;8:266-70.
7. Roach ES, Kiela AR. Pediatric Cerebrovascular Disorders. 2nd ed. New York: Futura; 1995. p. 329.
8. Johnston HH, Whittle IR, Besser M, Morgan MK. Vein of galen malformation: Diagnosis and management. Neurosurgery 1987;20:747-58.
9. Menezes AH, Graf CJ, Jacoby CG, Cornell SH. Management of vein of galen aneurysms: Report of two cases. J Neurosurg 1981;55:457-62.
10. Portnoy BA, Herion JC. Neurological manifestations in sickle-cell disease - with a review of the literature and emphasis on the prevalence of hemiplegia. Ann Intern Med 1972;76:643-52.
11. Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992;120:360-6.
12. Vomberg PP, Breeveld C, Fleury P, Arts WF. Cerebral thromboembolism due to antithrombin III deficiency in two children. Neuropediatrics 1987;18:42-4.
13. Koh S, Chen LS. Protein C and S deficiency in children with ischemic cerebrovascular accident. Pediatr Neurol 1997;17:319-21.
14. Mounes de Oea MA, Babron MC, Bietry O, Braugier M, Courtevonne V, Fontaine JL, et al. Thrombosis in systemic lupus erythematosus: A French collaborative study. Arch Dis Child 1991;66:713-7.
15. Selhub J, Jacques PF, Boston AG, D’Agostino RB, Wilson PW, Belanger A, et al. Association between plasma homocysteine concentrations and extraanural carotid-artery stenosis. N Engl J Med 1995;332:877-81.
16. Schoffner JM. Mitochondrial myopathy diagnosis. Neurol Clin 2000;18:103-23.
17. Suzuki J, Kodama N. Moyamoya disease: A review. Stroke 1983;14:194-9.
18. Golden G. Cerebrovascular disease. In. Pediatric neurological diseases. Ed. Swaiman K, CV Mosby, St. Louis. 1989, pp 603-617.
19. Deveber G, Andrew M. Cerebral sinovenous thrombosis in children. N Engl J Med 1997;337:417-25.
20. Lin CC, Lui CC, Tsai YL. Thalamic stroke secondary to straight sinus thrombosis in a nephrotic child. Pediatr Nephrol 2002;17:184-6.
21. Keene S, Gallagher A, Akeroyd S, McShane MA, Edge JA. Cerebral venous thrombosis during diabetic ketoacidosis. Arch Dis Child 2002;86:204-5.
22. Garcia JH, Ho Khang-Loon, Pantoni L. Pathology in Barnett. In: Henry JM, Mohr JP, Stein BM, Yatsu FM, editors. Stroke...
40. A dams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Castillo J. Deteriorating stroke: Diagnostic criteria, predictors, and prognostic signs. Arch Neurol 1998;55:481-6.

41. Hakim AM. Ischemic penumbra, the therapeutic window. Neurology 1998;51:844-6.

42. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol 1999;11:45-9.

43. Hademans GJ, Massoud TF. Biophysical mechanisms of stroke. Stroke 1997;28:2067-77.

44. Abruins HS. Lacunar disease. In: David B, editor. Child and Adolescent Neurology. St. Louis: Mosby; 1998. p. 271-93.

45. Yang JS, Park YD, Hartlage PL. Seizures associated with stroke in children. Pediatr Neurol 1995;12:136-8.

46. Pappachan J, Kirkham FJ. Cerebrovascular disease and stroke. Arch Dis Child 2008;93:890-8.

47. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. Malignant middle cerebral artery territory infarction: Clinical course and prognostic signs. Arch Neurol 1996;53:509-15.

48. Brust CM, Chamoorro A. Anterior cerebral artery diseases. In: Mohr JP, Choi DW, Grotta JC, Weir B, Wdf PA, editors. Stroke Pathophysiology, Diagnosis and Management. 4th ed. Philadelphia, PA: Churchill Livingstone; 2004. p. 101-11.

49. Scan I, Savitz MD, Louis R, Caplan MD. Vertebrobasilar disease. N Engl J Med 2005;352:2018-26.

50. Rosman NP, Wu JK, Caplan LR. Cerebellar infarction in the young. Stroke 1992;23:763-6.

51. Ramnauther RW, Sidler C, Mosso M, Georgiadis D. Ischemic lacunar stroke in patients with and without potential mechanism other than small-artery disease. Stroke 2003;34:653-9.

52. Samuel J, Fernandes CM. Lateral sinus thrombosis (a review of 45 cases). J Laryngol Otol 1987;101:1227-9.

53. Hacke W, Schwab S, Horn M, Spranger M, De Georgia M, von Kummer R. Malignant middle cerebral artery territory infarction: Clinical course and prognostic signs. Arch Neurol 1996;53:509-15.

54. Samuel J, Fernandes CM. Lateral sinus thrombosis (a review of 45 cases). J Laryngol Otol 1987;101:1227-9.

55. Lecker RR, Stein Er I. Features of dural sinus thrombosis simulating pseudotumor cerebri. Eur J Neurol 1999;6:601-4.

56. Roach ES, Meredith R, Golomb MR, Adams R, Biller J, Daniels S, et al. Management of stroke in infants and children. Stroke 2008;39:2044-691.

57. Roach ES, Meredith R, Golomb MR, Adams R, Biller J, Daniels S, et al. Management of stroke in infants and children. Stroke 2008;39:2044-691.

58. Reiber J, Graner MT, Wessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2009;25:1589-611.

59. Reiber J, Graner MT, Wessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2009;25:1589-611.

60. Reiber J, Graner MT, Wessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2009;25:1589-611.

61. Castillo J, Leira R, Garcia MM, Serena J, Blanco M, Davalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004;35:320-6.

62. Konstantinos Spengos K, Tsivgoulis G, Zakopoulos N. Biophysical mechanisms of stroke. Stroke 1997;28:2067-77.

63. Roach ES, Meredith R, Golomb MR, Adams R, Biller J, Daniels S, et al. Management of stroke in infants and children. Stroke 2008;39:2044-691.

64. Reiber J, Graner MT, Wessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2009;25:1589-611.

65. Reiber J, Graner MT, Wessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2009;25:1589-611.

66. Reiber J, Graner MT, Wessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2009;25:1589-611.

67. Reiber J, Graner MT, Wessner R, Morgenthaler M. Treatment of stroke on an intensive stroke unit: a novel concept. Intensive Care Med 2009;25:1589-611.
71. Lanthier S, Carmant L, David M, Larbissean A, de Veber G. Stroke in children: The coexistence of multiple risk factors predicts poor outcome. Neurology 2000;54:371-8.

72. Blom I, De Schryver EI, Kappelle LJ, Rinkel GJ, Jennekens-Schinkel A, Peters AC. Prognosis of haemorrhagic stroke in childhood: Long-term follow-up study. Dev Med Child Neurol 2003;45:233-9.

73. Sträter R, Becker S, von Eckardstein A, Heinecke A, Gutsche S, Junker R, et al. Prospective assessment of risk factors for recurrent stroke during childhood—a 5-year follow-up study. Lancet 2002;360:1540-5.

74. Ganesan V, Prengler M, Wade A, Kirkham FJ. Clinical and radiological recurrence after childhood arterial ischemic stroke. Circulation 2006;114:2170-7.

75. DeVeber GA, MacGregor D, Curtis R, Mayank S, et al. Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 2000;15:316-24.

76. Chabrier S, Hasson B, Lasjaunias P, Landrieu P, Tardieu M. Stroke in childhood: Outcome and recurrence risk by mechanism in 59 patients. J Child Neurol 2000;15:290-4.

77. Ganesan V, Hogan A, Shack N, Gordon A, Isaacs E, Kirkham FJ. Outcome after ischaemic stroke in childhood. Dev Med Child Neurol 2000;42:455-61.

78. Pavlovic J, Kaufmann F, Boltshauser E, Capone Mori A, GubserMercati D, Haenggeli CA, et al. Neuropsychological problems after paediatric stroke: Two year follow-up of Swiss children. Neuropediatrics 2006;37:13-9.

79. Salih MA, Abdel-Gader AG, Al-Jarallah AA, Keutab AY, Al-Nasser MN. Outcome of stroke in Saudi children. Saudi Med J 2006;27:891-6.

80. De Schryver EI, Blom I, Braun KP, Kappelle LJ, Rinkel GJ, Peters AC, et al. Long-term prognosis of cerebral venous sinus thrombosis in childhood. Dev Med Child Neurol 2004;46:514-9.

81. Ganesan V, Chong WK, Cox TC, Chawda SJ, Prengler M, Kirkham FJ, et al. Posterior circulation stroke in childhood: Risk factors and recurrence. Neurology 2002;59:1552-6.

82. Hogan AM, Kirkham FJ, Isaacs EB. Intelligence after stroke in childhood: Review of the literature and suggestions for future research. J Child Neuro 2000;15:325-32.

83. Max JE, Mathews K, Manes FF, Robertson BA, Fox PT, Lancaster JL, et al. Attention deficit hyperactivity disorder and neurocognitive correlates after childhood stroke. J Int Neuropsychol Soc 2003;9:815-29.

84. Max JE, Mathews K, Lansing AE, Robertson BA, Fox PT, Lancaster JL, et al. Psychiatric disorders after childhood stroke. J Am Acad Child Adolesc Psychiatry 2002;41:555-62.

85. Friefeld S, Yoseoh O, Jones JE, deVeber G. Health-related quality of life and its relationship to neurological outcome in child survivors of stroke. CNS Spectr 2004;9:465-75.

86. Delsing BJ, Catsman-Berrevoets CE, Appel IM. Early prognostic indicators of outcome in ischemic childhood stroke. Pediatr Neurol 2001;24:283-9.

87. Ganesan V, Ng V, Chong WK, Kirkham FJ, Connelly A. Lesion volume, lesion location, and outcome after middle cerebral artery territory stroke. Arch Dis Child 1999;81:295-300.

88. Boardman JP, Ganesan V, Rutherford MA, Saunders DE, Mercati E, Cowan F. Magnetic resonance imaging correlates of hemiparesis after neonatal and childhood middle cerebral artery stroke. Pediatrics 2005;115:321-6.

89. Hurvitz EA, Beale L, Ried S, Nelson VS. Functional outcome of paediatric stroke survivors. Pediatr Rehabil 1999;3:43-51.

Source of Support: Nil, Conflict of Interest: None declared.